[A Case of Successful Combination of Immune Checkpoint Inhibitors and Radiotherapy for MLH1 Gene-Deficient Colon Cancer].

Q4 Medicine

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-04-01

Yosuke Shimizu, Haruki Sada, Norimitsu Shimada, Masahide Miyata, Takahiro Fukuda, Michie Ono, Tomomasa Fujii, Yoshiyuki Shibata, Sho Taduma, Naoki Tanimine, Hirofumi Tazawa, Takahisa Suzuki, Takashi Onoe, Takeshi Sudo, Hirotaka Tashiro

{"title":"[A Case of Successful Combination of Immune Checkpoint Inhibitors and Radiotherapy for MLH1 Gene-Deficient Colon Cancer].","authors":"Yosuke Shimizu, Haruki Sada, Norimitsu Shimada, Masahide Miyata, Takahiro Fukuda, Michie Ono, Tomomasa Fujii, Yoshiyuki Shibata, Sho Taduma, Naoki Tanimine, Hirofumi Tazawa, Takahisa Suzuki, Takashi Onoe, Takeshi Sudo, Hirotaka Tashiro","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A 77-year-old woman was diagnosed with advanced transverse colon cancer(poorly differentiated adenocarcinoma)cT3N3H0P0, cStage Ⅲc and underwent extended left hemicolectomy in April 2020. The tumor tissue revealed RAS: wild type, BRAF: mutant type, dMMR(MLH1 deficiency)by immunochemical staining, and MSI-H by CDx. She received CAPOX as adjuvant chemotherapy after surgery. At the end of the 3 courses, she developed abdominal aortic lymph nodes recurrence( diameter 32×18 mm)and began to receive pembrolizumab therapy in August 2020. But the tumor re-grew 6 months after the start of this regimen. However the recurrent lesion was localized, radiation therapy(IMRT: 54 Gy/27 Fr) was added in combination with pembrolizumab. Two months later the tumor had shrunk significantly. As of June 2024, the patient has remained recurrence-free, suggesting that the abscopal effect may have been involved by immuno-radiotherapy in this case.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"342-344"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

A 77-year-old woman was diagnosed with advanced transverse colon cancer(poorly differentiated adenocarcinoma)cT3N3H0P0, cStage Ⅲc and underwent extended left hemicolectomy in April 2020. The tumor tissue revealed RAS: wild type, BRAF: mutant type, dMMR(MLH1 deficiency)by immunochemical staining, and MSI-H by CDx. She received CAPOX as adjuvant chemotherapy after surgery. At the end of the 3 courses, she developed abdominal aortic lymph nodes recurrence( diameter 32×18 mm)and began to receive pembrolizumab therapy in August 2020. But the tumor re-grew 6 months after the start of this regimen. However the recurrent lesion was localized, radiation therapy(IMRT: 54 Gy/27 Fr) was added in combination with pembrolizumab. Two months later the tumor had shrunk significantly. As of June 2024, the patient has remained recurrence-free, suggesting that the abscopal effect may have been involved by immuno-radiotherapy in this case.

本刊更多论文

【免疫检查点抑制剂联合放疗治疗MLH1基因缺陷结肠癌成功一例】。

一名77岁女性被诊断为晚期横贯结肠癌（低分化腺癌）cT3N3H0P0, cStageⅢc，并于2020年4月接受了延长左半结肠切除术。肿瘤组织显示RAS：野生型，BRAF：突变型，免疫化学染色dMMR（MLH1缺失），CDx染色MSI-H。术后接受CAPOX辅助化疗。3个疗程结束时，患者出现腹主动脉淋巴结复发（直径32×18 mm），并于2020年8月开始接受派姆单抗治疗。但是在这个治疗方案开始6个月后，肿瘤又重新生长了。然而，复发病灶是局部的，放疗（IMRT: 54 Gy/27 Fr）联合派姆单抗增加。两个月后，肿瘤明显缩小。截至2024年6月，患者仍无复发，提示本病例的体外效应可能涉及免疫放疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Cancer and Chemotherapy Medicine-Medicine (all)

CiteScore

0.20

自引率

0.00%

发文量

337